Reading time: 7 minutes Share this article: For decades, in the procurement ledgers of biopharmaceutical manufacturing, serum-derived Human Serum Albumin (HSA) often appears as a commodity staple. It is treated as a cost-effective stabilizer, typically priced in the market at approximately $5-$10 per gram. This price point, established by decades of plasma fractionation infrastructure, creates …
EXECUTIVE SUMMARY Raw material consistency is critical to reproducible biopharmaceutical manufacturing and cell culture performance. Human serum albumin (HSA) is widely used as a functional excipient, yet plasma-derived HSA (pHSA) exhibits structural heterogeneity and lot-to-lot variability that can affect downstream applications. Structural homogeneity directly influences ligand binding and conjugation performance. This application note presents a …
Reading time: 7 minutes Share this article: The biopharmaceutical supply chain is currently resting on a fragile foundation of animal- and human-derived raw materials. As the number of approved biologics and advanced therapies continues to grow, demand for serum-derived components is increasing against a finite and increasingly constrained supply base. This article examines four primary …
